Biotech | December 24, 2025
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Full approval will depend on verification of clinical benefit in a confirmatory trial
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The initiative is focused on a problem that continues to plague cancer outcomes in India
Subscribe To Our Newsletter & Stay Updated
